Product and Pipeline Analysis of the Global Vaccines Market : Expected Launches in the Areas of Cancer and Allergies Will Drive Growth

News provided by

Nov 18, 2014, 12:03 ET

NEW YORK, Nov. 18, 2014 /PRNewswire/ -- Executive Summary

•Vaccines are a class of biologics administered to prevent infectious diseases and reduce mortality and morbidity. It is estimated that vaccines have reduced the incidence of some diseases by more than xx%.
•Vaccines are now available for prevention of about xx infectious diseases.
•Coupled with powerful techniques such as polymerase chain reaction (PCR), mass spectrometry, and next- generation sequencing, the vaccine industry experienced a paradigm shift resulting in innovation and engineering of novel vaccines such as dendritic cell, DNA, and synthetic.
•The vaccine market is segmented into xx categories: infectious disease, cancer, allergy, and others (includes physiological diseases such as diabetes and Alzheimer's, as well as smoking cessation).
•Infectious disease vaccines—particularly viral vaccines—represent the largest share in terms of products under clinical trial. There is an increased focus on developing vaccines with alternative delivery routes, such as oral and intranasal, to effectively replace the conventional injection method of administration.
•One of the hallmarks of vaccine development is the improved understanding of the immune system. As a result, developers are pursuing vaccines for physiological diseases.
•Developers also are researching vaccines for emerging infectious diseases such as respiratory syncytial virus (RSV), norovirus, human immunodeficiency virus (HIV), Epstein-Barr, malaria, and Leishmaniasis.
•The market is dominated by xxbiopharmaceutical companies—Sanofi, GlaxoSmithKline (GSK), Merck & Co., Pfizer, and Novartis—that combined hold a nearly xx% global market share. The remaining xx% share is fragmented, represented by more than xx companies—the majority of them clinical-stage.
•Many vaccines are in the pipeline in various clinical stages. Successful outcomes are expected to boost the global market at a CAGR of xx% from 2014 to 2022.
•The United States, Europe, and Japan represent the largest markets for vaccine manufacturers; however, with increasing healthcare spending and awareness, emerging regions represent the fastest-growing and attractive markets.
•The vaccine market is perceived as an attractive, profitable venture because of its many opportunities. The overall impact of factors determining profitability is measured in a Porter's 5 forces analysis.
•While the market is attractive, the intensity of competition is high. It is imperative that companies adopt strategies to meet growing industry demands, such as innovation in or licensing technology platforms for vaccine development or alternative routes toward vaccine administration.
•The vaccine market is witnessing a paradigm shift because of an increasing focus on development of therapeutic vaccines. As a result, the industry is experiencing active collaborations, spin-offs, technological advances, and many active products in the pipeline.

Current Participant Strategies

•Large biopharma corporations' acquisitions to strengthen their product portfolios in emerging vaccine markets.
•Development of scalable and large-scale manufacturing by outsourcing clinical trials and manufacturing activities.
•Mutually beneficial collaborations and partnerships among companies of all sizes to develop vaccines.

Unmet Needs

•Economical and efficacious prophylactic vaccines in emerging markets.
•Long-term durability of vaccines for HIV, tuberculosis, and other re-emerging diseases.
•New administration routes, such as oral or sublingual.
•Vaccines for physiological disorders and cancer.

Potential Game-changing Strategies

•Technology-dependent development of a new class of vaccines for emerging infectious diseases.
•Development of both prophylactic and therapeutic vaccines to sustain market shares.
•Oral (sublingual, lingual) and needle-free vaccine delivery that increases end-user acceptance.
•Approaches that alleviate safety concerns among end users.

Read the full report: http://www.reportlinker.com/p02466784-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker